In an observational study, furosemide doses of 250 to 500 mg and spironolactone doses of 50 to 100 mg were independently associated with approximately 14% and 20% increased odds of hyponatremia, respectively.
Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.
Each 1-unit reduction in log-transformed urinary protein-creatinine ratio in patients with focal segmental glomerulosclerosis is associated with a 77% decreased risk of end-stage kidney disease, a study found.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
Lung metastases are most common in clear cell renal cell carcinoma, whereas lymph node metastases and liver metastases occur most frequently in papillary and chromophobe RCC, respectively, investigators reported.
Previous findings from the TIVO-3 trial showed that tivozanib offered superior progression-free survival compared with sorafenib in patients with refractory metastatic renal cell carcinoma, but the latest analysis found no significant difference in overall survival.
After receiving intense hormone therapy prior to radical prostatectomy, one-fifth of men with high-risk localized prostate cancer had no tumor or residual tumor smaller than 5 mm following surgery, a study found.
Almost 40% of men with metastatic castration-resistant prostate cancer experience radiographic disease progression while on second-generation hormone therapy despite stable or declining PSA, a study found.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
